Vaccinex Inc: Gains as lung cancer therapy shows positive data in early trial

Vaccinex

27/04/2020 16:27

** Shares of drug developer  VCNX.O  rise ~10% to $4.27
    ** Company says lung cancer patients receiving experimental
drug, pepinemab, along with immunotherapy treatment regimen
experienced clinical benefit in an early-stage trial
    ** 81% of immunotherapy-naïve patients experienced disease
control, either a partial response or disease stabilization, in
response to combination immunotherapy - VCNX
    ** Trial is being conducted in collaboration with Merck KGaA
 MRCG.DE 
    ** More than 291,292 shares traded, 11x their 25-day moving
avg
    ** Including session's gains, VCNX down 11.9% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))